Immunogenicity of SARS-CoV2 vaccines in patients with inflammatory bowel diseases an infliximab therapy.
In a British cohort, infliximab was associated with attenuated immunogenicity to a single dose of the BNT162b2 and ChAdOx1 nCoV-19 vaccines. Vaccination after SARS-CoV2 infection or a second dose of vaccine led to seroconversion in most patients. The second vaccine dose should therefore not be delayed.
Filgotinib (200 mg/day) was well tolerated and efficacious in inducing and maintaining remission compared with placebo in a phase 2b/3 trial program (SELECTION).
The subcutaneous infliximab biosimilar CT-P13 was non-inferior to intravenous application during maintenance therapy with regard to efficacy, safety and immunogenicity.
A nationwide Swedish cohort study shows that all histological NAFLD stages are associated with significantly increased overall mortality with the risk increasing with stage (simple steatosis – steatohepatitis – fibrosis – cirrhosis). Most of this excess mortality was due to extrahepatic cancer and cirrhosis, while the contributions from cardiovascular disease and hepatocellular carcinoma were lower.
Diagnosis of Wilson disease based on laboratory or genetic parameters is often difficult. A current study shows that the determination of ATP7B peptides is highly effective in the diagnosis of Wilson disease (sensitivity 91.2%, specificity 98.1%, positive predictive value 98%, negative predictive value 91.5%). This also applied to Wilson disease patients with normal ceruloplasmin levels or ambiguous genetic results.
A recent South Korean study reveals that risks of hepatocellular carcinoma (HCC) and clinical events do not differ significantly between spontaneous and therapy-induced HBsAg seroclearance. However, the annual HCC risk exceeds the recommended cut-off for HCC surveillance even after HBsAg seroclearance, suggesting that continued HCC surveillance is required. Future studies need to clarify whether these Asian study results also apply to e.g. European cohorts.
Oesophagus Stomach Duodenum
Checkpoint inhibition as first-line therapy for advanced gastric, gastroesophageal junction and esophageal adenocarcinoma.
Nivolumab plus chemotherapy resulted in superior overall survival as well as progression-free survival as compared to chemotherapy alone in a phase 3 trial and represents a new standard of first-line treatment for these patients.
In a proof-of-concept study, immune modulating gliadin nanoparticles (TAK-101) were well tolerated and prevented gluten-induced immune activation in patients with celiac disease. These findings suggest that antigen-specific tolerance was induced indicating that TAK-101 may represent a promising approach to treat celiac disease.
Efficacy and safety of endotherapy using fully covered metal stents is non-inferior to repeated stenting with plastic. However, metal stents were associated with fewer interventions.